-
2025-521521-33-00
10
2026-04-02
Kidney transplant rejection
-
2025-522191-86-00
5
2026-04-02
Focal segmental glomerulosclerosis
-
2025-522279-27-00
5
2026-04-02
Newly Diagnosed AML with an NPM1 mutation
-
2025-523204-68-00
4
2026-03-25
HER2-positive breast cancer
-
2025-523160-20-00
1
2026-03-23
Advanced solid tumors
-
2025-521314-25-00
5
2026-03-19
NPM1-m and KMT2A-r Acute Myeloid Leukemia
-
2024-519444-33-00
5
2026-03-12
HER2-expressing endometrial cancer (IHC 3+/2+)
-
2025-520805-10-00
5
2026-03-12
Chronic inflammatory demyelinating polyneuropathy (CIDP)
-
2025-520675-86-00
4
2026-03-10
Unresectable or Metastatic Hepatocellular Carcinoma and Compensated Li
-
2025-522033-64-00
1
2026-02-26
Myelofibrosis
-
2024-520353-21-00
3
2026-02-24
Myeloproliferative Neoplasms
-
2025-521558-40-00
5
2026-02-12
Pulmonary Hypertension Associated with Interstitial Lung Disease
-
2025-521831-35-00
6
2026-02-12
Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
-
2025-521852-45-00
4
2026-01-22
Cutaneous T-Cell Lymphoma
-
2025-521797-34-00
5
2026-01-20
Diabetes Mellitus, Type 1
-
2024-520433-76-00
4
2026-01-08
Newly Diagnosed Multiple Myeloma
-
2024-520097-36-00
5
2026-01-07
Chronic inflammatory demyelinating polyneuropathy (CIDP)
-
2025-522052-13-00
10
2025-12-24
Framework for Optimizing, Refining, and Unifying Management of HSCT in
-
2023-507525-42-00
5
2025-12-23
Endometrial cancer
-
2023-505661-89-00
4
2025-12-19
Early-stage, Hormone Receptor (HR)-positive / Human Epidermal Growth F
-
2024-518899-31-00
5
2025-12-19
Variant or wild-type transthyretin (TTR) amyloid cardiomyopathy
-
2025-521672-60-00
7
2025-12-19
Metastatic or locally advanced SST2-positive neuroendocrine neoplasms
-
2025-521299-76-00
7
2025-12-18
Relapsed or refractory acute leukaemia or Myelodysplastic Syndromes wi
-
2025-522070-36-00
5
2025-12-15
immune thrombocytopenia (ITP)